OncoMatch/Clinical Trials/NCT06816134
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Is NCT06816134 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TmBU conditioning Regimen and mBUCY conditioning regimen for acute myeloid leukemia.
Treatment: TmBU conditioning Regimen · mBUCY conditioning regimen — This project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The TmBU scheme or modified Bu/Cy (mBuCy) scheme was used for pretreatment in allo-HSCT. The primary endpoint of the study was the 2-year cumulative incidence of relapse (CIR) after allo-HSCT, and the secondary endpoints were 2-year overall survival rate (OS), progressing-free survival rate (PFS), non-relapse mortality rate (NRM), graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) rate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage RELAPSED, PRIMARY REFRACTORY, HIGH-RISK AT DIAGNOSIS, MRD POSITIVE BEFORE TRANSPLANTATION
Relapsed/primary refractory ... or genetic high-risk group AML at diagnosis ... High-risk at diagnosis ... or MRD positive before transplantation B-ALL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
creatinine clearance ≥ 50ml/min
Liver function
alt and ast ≤ 2.5 times the upper limit of the normal range, and total bilirubin ≤ 1.5 times the upper limit of the normal range
Cardiac function
cardiac nyha grade ≤ 2, left ventricular ejection fraction ≥55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06816134 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage RELAPSED or PRIMARY REFRACTORY or HIGH-RISK AT DIAGNOSIS or MRD POSITIVE BEFORE TRANSPLANTATION is required.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 15 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify